Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS vs BIMEKIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS vs BIMEKIZUMAB: Safety Overview

Metric BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS BIMEKIZUMAB
Total FAERS Reports 176 2,459
Deaths Reported 0 31
Death Rate N/A 1.3%
Hospitalizations 110 565
Average Patient Age 66.0 yrs 52.9 yrs
% Female Patients 91.7% 59.9%
Manufacturer N/A UCB, Inc.
Route N/A SUBCUTANEOUS